Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sol-Gel Technologies Ltd (SLGL)

Sol-Gel Technologies Ltd (SLGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,047
  • Shares Outstanding, K 27,858
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -27,240 K
  • 60-Month Beta 1.33
  • Price/Sales 16.85
  • Price/Cash Flow N/A
  • Price/Book 0.54
Trade SLGL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.09
  • Most Recent Earnings $-0.17 on 03/13/24
  • Latest Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 621.21% ( -559.70%)
  • Historical Volatility 67.16%
  • IV Percentile 91%
  • IV Rank 52.05%
  • IV High 1,180.91% on 04/18/24
  • IV Low 13.60% on 08/18/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 85
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 424
  • Open Int (30-Day) 409

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +63.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7900 +17.11%
on 04/08/24
1.0700 -13.53%
on 04/03/24
-0.0548 (-5.59%)
since 03/22/24
3-Month
0.7900 +17.11%
on 04/08/24
1.5754 -41.27%
on 02/01/24
-0.2348 (-20.24%)
since 01/23/24
52-Week
0.7900 +17.11%
on 04/08/24
4.0498 -77.15%
on 07/21/23
-2.9548 (-76.15%)
since 04/21/23

Most Recent Stories

More News
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

SLGL : 0.9252 (-1.05%)
SENS : 0.4300 (+7.82%)
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates

Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FIXX : 0.9347 (+0.77%)
SLGL : 0.9252 (-1.05%)
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AMPH : 40.91 (+1.84%)
SLGL : 0.9252 (-1.05%)
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies

Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.

RDY : 71.49 (-0.91%)
AMPH : 40.91 (+1.84%)
SLGL : 0.9252 (-1.05%)
3 Generic Drug Stocks to Watch Amid Inflation Pressures

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

RDY : 71.49 (-0.91%)
AMPH : 40.91 (+1.84%)
SLGL : 0.9252 (-1.05%)
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

SLGL : 0.9252 (-1.05%)
FIXX : 0.9347 (+0.77%)
Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BHC : 8.53 (+0.95%)
SLGL : 0.9252 (-1.05%)
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel

Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.

RDY : 71.49 (-0.91%)
TEVA : 13.01 (+1.01%)
SLGL : 0.9252 (-1.05%)
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

TEVA : 13.01 (+1.01%)
RDY : 71.49 (-0.91%)
SLGL : 0.9252 (-1.05%)
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SLGL : 0.9252 (-1.05%)
FIXX : 0.9347 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for...

See More

Key Turning Points

3rd Resistance Point 1.0082
2nd Resistance Point 0.9916
1st Resistance Point 0.9584
Last Price 0.9252
1st Support Level 0.9086
2nd Support Level 0.8920
3rd Support Level 0.8588

See More

52-Week High 4.0498
Fibonacci 61.8% 2.8046
Fibonacci 50% 2.4199
Fibonacci 38.2% 2.0352
Last Price 0.9252
52-Week Low 0.7900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar